27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our findings demonstrate the importance of community-based patient-centered care strategies for stroke survivors that address their range of health needs and prevent more costly acute care use. 2 key findings →
Design: cohort study Participants: 29,673 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In our final study sample (N = 21,558), significant difference in survival among index AD medication groups were observed with donepezil being associated with better survival than memantine, and oral and transdermal forms of rivastigmine for both ITT and as-treated analysis. 3 key findings →
Design: cohort study Participants: 21,558 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Two thirds (66%) of adult child caregivers in the control condition admitted their parent to a residential care setting compared with 37% in the treatment condition. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
20% of individuals with newly identified dementia were homebound and this group was more functionally impaired, medically complex, and socioeconomically disadvantaged as compared to the non-homebound. 5 key findings →
Design: prospective cohort Participants: 939 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Of 23 892 individuals moving-in to care homes, 20 250 (84.8%) died by 31 May 2020. 5 key findings →
Design: cohort study Participants: 892 Evidence: moderate
Full summary, score breakdown and related studies → Original source
US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. 5 key findings →
Design: systematic-review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Use of donepezil by AD patients resulted in significant delays in NHP. 2 key findings →
Design: open-label trial Participants: 1,115 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Existing studies have included a narrow range of infectious diseases, relied on short follow-up periods, and provided little evidence for whether the increased risk is limited to specific dementia subtypes or attributable to specific microbes rather than infection burden. 5 key findings →
Design: cohort study Participants: 490 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia diagnosis recording in general hospitals is increasing but remains less likely in some groups. 1 key finding →
Design: cohort study Participants: 21,387 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Residents enrolled in managed care (n = 133) were more likely to have do-not-hospitalize orders compared with those in traditional Medicare fee for service (n = 158) (63.7% vs 50.9%; adjusted odds ratio, 1.9; 95% CI, 1.1-3.4), were less likely to be transferred to the hospital for acute illness (3.8% vs 15.7%; adjusted odds ratio, 0.2; 95% CI, 0.1-0.5), had more primary care visits per 90 days (mean [SD], 4.8 [2.6] vs 4.2 [5.0]; adjusted rate ratio, 1.3; 95% CI, 1.1-1.6), and had more nurse practitioner visits (3.0 [2.1] vs 0.8 [2.6]; adjusted rate ratio, 3.0; 95% CI, 2.2-4.1). 3 key findings →
Design: cohort study Participants: 133 Evidence: moderate
Full summary, score breakdown and related studies → Original source
It is associated with increases in mortality, physical morbidity, length of hospital stay, institutionalisation and costs to healthcare providers. 4 key findings →
Participants: 833 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The cohort sample included 5058 beneficiaries with dementia (mean [SD] age, 85.5 [8.0] years; 3038 women [60.1%]; 809 [16.0%] non-Hispanic Black, 357 [7.1%] Hispanic, and 3892 non-Hispanic White respondents [76.9%]). 4 key findings →
Design: cohort study Participants: 5,058 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Antipsychotic initiation and use were common during hospitalization, most often for delirium, and individuals were frequently discharged on these medications. 3 key findings →
Design: cohort study Participants: 17,775 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Family members of persons with advanced dementia may be asked to make complex treatment decisions without having adequate knowledge regarding the risks and benefits. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Patients with dementia are significantly more likely to be disenrolled from hospice following a long enrollment period compared with patients without dementia. 5 key findings →
Design: cohort study Participants: 149,814 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Quality of life of people with advanced dementia living in nursing homes is often suboptimal. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Use of VR in hospitalized patients significantly reduces pain versus a control distraction condition. 5 key findings →
Design: cohort study Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source
A simple exercise program, 1 hour twice a week, led to significantly slower decline in ADL score in patients with AD living in a nursing home than routine medical care. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Incident use of neuroleptics in Ontario nursing homes is substantial. 3 key findings →
Design: cohort study Participants: 19,780 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The PROMPPT trial will assess whether review by trained clinical pharmacists working in general practices can support safe opioid reduction without compromising pain management and quality of life. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
This Swedish study of over 1,200 people with memory symptoms found that a blood test combining p-tau217 with an amyloid ratio (the 'Amyloid Probability Score 2') was far more accurate at identifying Alzheimer's disease than doctors' clinical judgment alone. 3 key findings →
Design: cross-sectional Participants: 1,213 Evidence: high
Full summary, score breakdown and related studies → Original source
We were unable to detect a difference in HRQOL for screening for ADRD among older adults. 3 key findings →
Design: randomized controlled trial Participants: 2,008 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Pre- and postoperative orthogeriatric care given in an acute geriatric ward was not effective in reducing delirium or long-term cognitive impairment in patients with hip fracture. 5 key findings →
Design: randomized controlled trial Participants: 329 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The rising prevalence of dementia will have an impact on acute hospitals. 1 key finding →
Design: cohort study Participants: 617 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Although loneliness and social isolation have been linked to an increased risk of non-communicable diseases such as cardiovascular disease and dementia, their association with the risk of severe infection is uncertain. 4 key findings →
Design: cohort study Participants: 905 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
10 of the 973 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →